Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58940 | 0.78 | MAPT (0.38) | MAPTKMT2AGALR3 | |
| SCHEMBL11405724 | 0.77 | KMT2A (0.38) | MAPTKMT2AGALR3 | |
| SCHEMBL58879 | 0.75 | GALR3 (0.38) | KMT2AGALR3 | |
| SCHEMBL13909523 | 0.75 | MAPT (0.36) | MAPTKMT2AGALR3 | |
| SCHEMBL13519754 | 0.71 | KMT2A (0.31) | KMT2A | |
| SCHEMBL15282119 | 0.69 | GALR3 (0.34) | KMT2AGALR3 | |
| SCHEMBL5180050 | 0.67 | MAPT (0.35) | MAPTKMT2A | |
| SCHEMBL3108876 | 0.65 | MAPT (0.31) | MAPT | |
| SCHEMBL5179878 | 0.65 | MAPT (0.33) | MAPTKMT2A | |
| SCHEMBL3676705 | 0.64 | MAPT (0.38) | MAPTKMT2AGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100526300-C | Method of manufacturing 4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2009-08-12 | — | — | CN | disclosed |
| US-7569702-B2 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1720838-B1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | EP | disclosed |
| CN-1922154-A | Method for producing 4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1720838-A1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077913-A1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | COX4I1, GTF3C5, CYP4X1 | MAPT 4488/4885KMT2A 1832/4885GALR3 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.